Literature DB >> 11426320

The human gene for mannan-binding lectin-associated serine protease-2 (MASP-2), the effector component of the lectin route of complement activation, is part of a tightly linked gene cluster on chromosome 1p36.2-3.

C Stover1, Y Endo, M Takahashi, N J Lynch, C Constantinescu, T Vorup-Jensen, S Thiel, H Friedl, T Hankeln, R Hall, S Gregory, T Fujita, W Schwaeble.   

Abstract

The proteases of the lectin pathway of complement activation, MASP-1 and MASP-2, are encoded by two separate genes. The MASP1 gene is located on chromosome 3q27, the MASP2 gene on chromosome 1p36.23-31. The genes for the classical complement activation pathway proteases, C1r and C1s, are linked on chromosome 12p13. We have shown that the MASP2 gene encodes two gene products, the 76 kDa MASP-2 serine protease and a plasma protein of 19 kDa, termed MAp19 or sMAP. Both gene products are components of the lectin pathway activation complex. We present the complete primary structure of the human MASP2 gene and the tight cluster that this locus forms with non-complement genes. A comparison of the MASP2 gene with the previously characterised C1s gene revealed identical positions of introns separating orthologous coding sequences, underlining the hypothesis that the C1s and MASP2 genes arose by exon shuffling from one ancestral gene.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11426320     DOI: 10.1038/sj.gene.6363745

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  9 in total

Review 1.  Molecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2.

Authors:  Dong Liu; Jian-Ying Zhu; Zhong-Xiang Niu
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

Review 2.  Mannan-binding-lectin-associated serine proteases, characteristics and disease associations.

Authors:  Rikke Sørensen; Steffen Thiel; Jens C Jensenius
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

3.  Organization of the MASP2 locus and its expression profile in mouse and rat.

Authors:  Cordula M Stover; Nicholas J Lynch; Steven J Hanson; Michaela Windbichler; Simon G Gregory; Wilhelm J Schwaeble
Journal:  Mamm Genome       Date:  2004-11       Impact factor: 2.957

4.  A Drosophila model for TDP-43 proteinopathy.

Authors:  Yan Li; Payal Ray; Elizabeth J Rao; Chen Shi; Weirui Guo; Xiaoping Chen; Elvin A Woodruff; Kazuo Fushimi; Jane Y Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-26       Impact factor: 11.205

5.  Association of MASP-2 levels and MASP2 gene polymorphisms with rheumatoid arthritis in patients and their relatives.

Authors:  Isabela Goeldner; Thelma Skare; Angelica B W Boldt; Flavia R Nass; Iara J Messias-Reason; Shirley R Utiyama
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

6.  Effects of hMASP-2 on the formation of BCG infection-induced granuloma in the lungs of BALB/c mice.

Authors:  Xiaoying Xu; Xiaoling Lu; Xingfang Dong; Yanping Luo; Qian Wang; Xun Liu; Jie Fu; Yuan Zhang; Bingdong Zhu; Xingming Ma
Journal:  Sci Rep       Date:  2017-05-23       Impact factor: 4.379

7.  MASP2 gene polymorphism is associated with susceptibility to hepatitis C virus infection.

Authors:  Siumara Tulio; Fabio R Faucz; Renata I Werneck; Márcia Olandoski; Rodrigo B Alexandre; Angélica B W Boldt; Maria Lucia Pedroso; Iara J de Messias-Reason
Journal:  Hum Immunol       Date:  2011-07-31       Impact factor: 2.850

Review 8.  MBL-associated serine proteases (MASPs) and infectious diseases.

Authors:  Marcia H Beltrame; Angelica B W Boldt; Sandra J Catarino; Hellen C Mendes; Stefanie E Boschmann; Isabela Goeldner; Iara Messias-Reason
Journal:  Mol Immunol       Date:  2015-04-08       Impact factor: 4.407

9.  Mannose-Binding Lectin (MBL) and MBL-associated serine protease-2 (MASP-2) in women with malignant and benign ovarian tumours.

Authors:  Anna St Swierzko; Agnieszka Szala; Sambor Sawicki; Janusz Szemraj; Marcin Sniadecki; Anna Sokolowska; Andrzej Kaluzynski; Dariusz Wydra; Maciej Cedzynski
Journal:  Cancer Immunol Immunother       Date:  2014-07-20       Impact factor: 6.968

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.